Form 13-F position report

CUE BIOPHARMA INC

Reported by MORGAN STANLEY

Company profile Manager portfolio Source filing
CUE CUSIP 22978P106 Manager CIK 0000895421
Latest reported change

Reported 0 shares, down 18,374 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2026
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 34 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Reduced 0 -18,374 (-100.0%) 0 $0 2026-08-13
Q1 2026 Reduced 18,374 -220 (-1.2%) < 0.01% $4,224 2026-05-15
Q4 2025 Reduced 18,594 -8,917 (-32.4%) < 0.01% $5,679 2026-02-13
Q3 2025 Reduced 27,511 -1,940 (-6.6%) < 0.01% $19,772 2025-11-14
Q2 2025 Added 29,451 +760 (2.6%) < 0.01% $20,095 2025-08-15
Q1 2025 Reduced 28,691 -2 (0.0%) < 0.01% $26,138 2025-05-15
Q4 2024 Reduced 28,693 -4,998 (-14.8%) < 0.01% $31,276 2025-02-14
Q3 2024 Reduced 33,691 -87,308 (-72.2%) < 0.01% $25,511 2024-11-14
Q2 2024 Reduced 120,999 -28,877 (-19.3%) < 0.01% $150,039 2024-08-14
Q1 2024 Reduced 149,876 -14,830 (-9.0%) < 0.01% $283,266 2024-05-15
Q4 2023 Added 164,706 +40,168 (32.3%) < 0.01% $434,824 2024-02-13
Q3 2023 Added 124,538 +18,725 (17.7%) < 0.01% $286,437 2023-11-15
Q2 2023 Added 105,813 +6,888 (7.0%) < 0.01% $386,218 2023-08-14
Q1 2023 Reduced 98,925 -79,871 (-44.7%) < 0.01% $353,162 2023-05-15
Q4 2022 Reduced 178,796 -76,512 (-30.0%) < 0.01% $509,570 2023-02-14
Q3 2022 Reduced 255,308 -179,700 (-41.3%) < 0.01% $569,000 2022-11-14
Q2 2022 Added 435,008 +236,429 (119.1%) < 0.01% $1,084,000 2022-08-15
Q1 2022 Added 198,579 +21,940 (12.4%) < 0.01% $969,000 2022-05-13
Q4 2021 Reduced 176,639 -297,494 (-62.7%) < 0.01% $1,998,000 2022-02-14
Q3 2021 Added 474,133 +46,905 (11.0%) < 0.01% $6,909,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

54 managers reported CUE BIOPHARMA INC for Q2 2026.

Manager Activity Shares Change % of reported 13F Reported value Tenure
IFP Advisors Inc Added 100 +96 < 0.01% $55 11 qtrs
MORGAN STANLEY This report Reduced 0 -18,374 0 $0 34 qtrs
BlackRock Inc Reduced 0 -449,161 0 $0 8 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 0 -24,614 0 $0 25 qtrs
SeaCrest Wealth Management LLC Reduced 0 -10,000 0 $0 23 qtrs
UMA Financial Services Inc Reduced 0 -1,006 0 $0 7 qtrs
XTX Topco Ltd Reduced 0 -15,124 0 $0 8 qtrs
Beacon Pointe Advisors LLC Reduced 0 -10,000 0 $0 2 qtrs
LPL Financial LLC Reduced 0 -15,590 0 $0 16 qtrs
BNP PARIBAS FINANCIAL MARKETS Reduced 0 -415 0 $0 34 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.